RankingsPricing
  1. US-listed companies
  2. TEVA PHARMACEUTICAL INDUSTRIES LTD
  3. Financials
  4. Cash and cash equivalents

TEVA PHARMACEUTICAL INDUSTRIES LTDTEVA

Market cap
$28.4B
P/E ratio
SummaryFinancials
Period EndCash and cash equivalents (Million USD)YoY (%)
Dec 31, 20243,300+2.26%
Dec 31, 20233,227+13.87%
Dec 31, 20222,834+28.94%
Dec 31, 20212,198+0.96%
Dec 31, 20202,177+10.23%
Dec 31, 20191,975+10.83%
Dec 31, 20181,782+85.05%
Dec 31, 2017963-2.53%
Dec 31, 2016988-85.78%
Dec 31, 20156,946+212.04%
Dec 31, 20142,226+114.45%
Dec 31, 20131,038-63.95%
Dec 31, 20122,879+162.68%
Dec 31, 20111,096-12.18%
Dec 31, 20101,248

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating income Operating expenses Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSAdjusted EPSDividend payout ratio (%)Dividend per shareAdjusted DPSEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)